☆ 4.7 Article

Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19 A Meta-analysis

JAMA NETWORK OPEN (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma

Hyung Park et al.

Summary: This study aimed to develop an index for predicting the relative treatment benefit from COVID-19 convalescent plasma (CCP) compared to treatment without CCP. The study found that CCP treatment may be most effective for patients with preexisting conditions and those in the early stages of COVID-19.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Editorial Material Psychiatry

Prediction, Not Association, Paves the Road to Precision Medicine

Danilo Bzdok et al.

JAMA PSYCHIATRY (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Emerging Lessons From COVID-19 for the US Clinical Research Enterprise

Derek C. Angus et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Medicine, General & Internal

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Stephen A. Klassen et al.

Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.

MAYO CLINIC PROCEEDINGS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

Katharine J. Bar et al.

Summary: This study assessed the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia, showing significant benefits in clinical severity score and 28-day mortality. The results suggest that CCP may benefit select populations, especially those with comorbidities who are treated early.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Medicine, General & Internal

The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement

David M. Kent et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Severe Covid-19

David A. Berlin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Mild or Moderate Covid-19

Rajesh T. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks

Denise J. Wooding et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

添加到收藏夹

Article Health Care Sciences & Services

Do we need to adjust for interim analyses in a Bayesian adaptive trial design?

Elizabeth G. Ryan et al.

BMC MEDICAL RESEARCH METHODOLOGY (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

Pooling Data From Individual Clinical Trials in the COVID-19 Era

Eva Petkova et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Medicine, General & Internal

Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)

Sophie Juul et al.

SYSTEMATIC REVIEWS (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

COVID-19 and the Path to Immunity

David S. Stephens et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes JACC Focus Seminar

Sean P. Pinney et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection Illness Beyond Acute Infection and Public Health Implications

S. Deblina Datta et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, Research & Experimental

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos et al.

TRIALS (2020)

添加到收藏夹

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Review Medicine, General & Internal

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both

Janet Woodcock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Medicine, General & Internal

Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement

Lesley A. Stewart et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

添加到收藏夹

Article Education & Educational Research

Why We (Usually) Don't Have to Worry About Multiple Comparisons

Andrew Gelman et al.

JOURNAL OF RESEARCH ON EDUCATIONAL EFFECTIVENESS (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.